Arrhythmic complications of tyrosine kinase inhibitors

Future Cardiology

Volumn 11, Issue 4, 2015, Pages 395-399

  Fradley, Michael G ^a   Pinilla Ibarz, Javier ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Arrhythmia; Atrial fibrillation; Cancer treatment; Cardiotoxicity; Chemotherapy; QT prolongation; Torsades de Pointes; Tyrosine kinase inhibitors

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FUNCTION; HUMAN; NOTE; PRIORITY JOURNAL; SURVIVAL RATE; ANTAGONISTS AND INHIBITORS; ARRHYTHMIAS, CARDIAC; CHEMICALLY INDUCED;

ARRHYTHMIAS, CARDIAC; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84939425482     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/FCA.15.42     Document Type: Note

References (34)

1. Lal H, Kolaja KL, Force T. Cancer genetics and the cardiotoxicity of the therapeutics. J. Am. Coll. Cardiol. 61(3), 267-274 (2013).
2. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353(2), 172-187 (2005).
3. Hasinoff BB. The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicol. Appl. Pharmacol. 244(2), 190-195 (2010).
4. Tamargo J, Caballero R, Delpon E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf. 38(2), 129-152 (2015).
5. Curigliano G, Spitaleri G, Fingert HJ et al. Drug-induced qtc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Eur. J. Cancer 44(4), 494-500 (2008).
6. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 36(5), 295-316 (2013).
7. Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J. Clin. Oncol. 25(22), 3362-3371 (2007).
8. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370(9604), 2011-2019 (2007).
9. Zang J, Wu S, Tang L et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS One 7(2), e30353 (2012).
10. Locatelli M, Criscitiello C, Esposito A et al. QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review. Target Oncol. 10(1), 27-43 (2015).
11. Tam CS, Kantarjian H, Garcia-Manero G et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 112(3), 516-518 (2008).
12. Zhang DY, Wang Y, Lau CP, Tse HF, Li GR. Both EGFR kinase and Src-related tyrosine kinases regulate human ether-à-go-go-related gene potassium channels. Cell Signal. 20(10), 1815-1821 (2008).
13. Lu Z, Wu CY, Jiang YP et al. Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Sci. Transl. Med. 4(131), 131ra150 (2012).
14. Yang T, Chun YW, Stroud DM et al. Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current. Circulation 130(3), 224-234 (2014).
15. Rutledge CA, Ng FS, Sulkin MS et al. c-Src kinase inhibition reduces arrhythmia inducibility and connexin43 dysregulation after myocardial infarction. J. Am. Coll. Cardiol. 63(9), 928-934 (2014).
16. Morgan TK Jr., Sullivan ME. An overview of class III electrophysiological agents: a new generation of antiarrhythmic therapy. Prog. Med. Chem. 29, 65-108 (1992).
17. Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127(1), e6-e245 (2013).
18. O'neal WT, Lakoski SG, Qureshi W et al. Relation between cancer and atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study). Am. J. Cardiol. 115(8), 1090-1094 (2015).
19. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J. Am. Coll. Cardiol. 63(10), 945-953 (2014).
20. Mego M, Reckova M, Obertova J, Sycova-Mila Z, Brozmanova K, Mardiak J. Increased cardiotoxicity of sorafenib in sunitinibpretreated patients with metastatic renal cell carcinoma. Ann. Oncol. 18(11), 1906-1907 (2007).
21. Xu Z, Cang S, Yang T, Liu D. Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia thereapy. Hematol. Rev. 1(e4), 17-21 (2009).
22. Wang ML, Rule S, Martin P et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369(6), 507-516 (2013).
23. Byrd JC, Brown JR, O'brien S et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl. J. Med. 371(3), 213-223 (2014).
24. Pretorius L, Du XJ, Woodcock EA et al. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. Am. J. Pathol. 175(3), 998-1009 (2009).
25. Chong E, Chang SL, Hsiao YW et al. Resveratrol, a red wine antioxidant, reduces atrial fibrillation susceptibility in the failing heart by PI3K/AKT/eNOS signaling pathway activation. Heart Rhythm 12(5), 1046-1056 (2015).
26. Singhal R, Chang SL, Chong E et al. Colchicine suppresses atrial fibrillation in failing heart. Int. J. Cardiol. 176(3), 651-660 (2014).
27. Craxton A, Jiang AM, Kurosaki T, Clark EA. Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt. J. Biol. Chem. 274(43), 30644-30650 (1999).
28. Mcmullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-AKT signaling. Blood 124(25), 3829-3830 (2014).
29. Furman RR, Sharman JP, Coutre SE et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370(11), 997-1007 (2014).
30. Gopal AK, Kahl BS, De Vos S et al. PI3K? inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370(11), 1008-1018 (2014).
31. Lannutti BJ, Meadows SA, Herman SE et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117(2), 591-594 (2011).
32. Davis RE, Ngo VN, Lenz G et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277), 88-92 (2010).
33. Wiestner A. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J. Clin. Oncol. 31(1), 128-130 (2013).
34. Yang T, Yang P, Roden DM, Darbar D. Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation. Heart Rhythm 7(9), 1246-1252 (2010).